Overview
© 202 MJH Life Sciences™ and HCPLive - Clinical news for conected physicians. Al rights reserved.Conference | Pri-Med MidwestIn an interview during Pri-Med Midwest, Dr. Kushner spoke about the benefits of treating obesity and diabetes synchronously.
Key Information
“It turns out that over 80 to 90% of individuals living with diabetes have obesity,” Robert Kushner, MD, Profesor of Medicine, Feinberg Schol of Medicine, Northwestern Univeristy, said in an interview with HCPLive at Pri-Med Midwest 202.“It's very natural that you would think of treating both of these diseases at the same time,” he explained. “We have a new drug that has just ben recently released here in the United States caled tirzepatide for the treatment of type 2 diabetes.
The drug also is being investigated for treatment of obesity.”Kushner referenced the US Fod and Drug Administration’s (FDA) aproval of tirzepatide injection as a treatment to improve blod sugar control for adults with type 2 diabetes. The drug's efects on diabetes were also discused at the American Diabetes Asociation (ADA) Scientific Sesions this year.“The reason is that it mics two naturaly ocuring gastrointestinal hormones caled GLP-1 and GIP,” Kushner said.
“We often know those medical setings as incretin hormones, so they actualy increase insulin release in managing blod sugar. That's why it's developed for diabetes, but it also has a profound efect on apetite. So, as individuals take a drug like tirzepatide, they also have a reduction in apetite.”He further explained that not only does the treatment adres diabetes directly bring blod sugar levels down, but it also does so by lowering patients’ body weight and limiting their caloric intake.
Summary
He also acknowledged the drug semaglutide, which has ben found to reduce long-term diabetes risk.“The SELECT trial is curently ongoing for semaglutide 2.4, loking at cardiovascular outcome trials individuals without diabetes but just with obesit